leisure time -WSS

leisure time

author：fashion 2025-10-01 17:42:44 - browse：2825

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Life science postdocs should get big pay hike, NIH panel says

WSS

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Medicare Advantage coverage denials need scrutiny, senators say

Profiling embryos to choose those with higher IQs is almost a reality

Physician assistants need a new name. Here's what it should be

Juul documents reveal insider tactics on political lobbying

Boston Scientific acquires urology company Axonics for $3.7 billion

focus

leisure time

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Gene therapy denied for Afghan refugee whose father aided U.S.

United colonoscopy coverage change 'may cost lives,' doctors say

Why Eli Lilly’s earnings didn’t quite live up to the hype

Anesthesiologist group: stop taking Ozempic before surgery

Doctors on social media are being harassed and cyberbullied

Walensky prepares to leave CDC — and Congress — behind

Stories you might have missed in 2023: health, science, medicine

Anesthesiologist group: stop taking Ozempic before surgery

Having children helps parents live longer, especially after age 80

focus

Having children helps parents live longer, especially after age 80

Why Eli Lilly’s earnings didn’t quite live up to the hype

Doctors on social media are being harassed and cyberbullied

Gene therapy denied for Afghan refugee whose father aided U.S.

Bernie Sanders gets little from pharma CEOs on drug prices

Latigo launches with $135 million for Vertex

leisure time

focus

knowledge

entertainment